Advertisement

Antimicrobial Prophylaxis in High-Risk Oncology Patients

  • Jeffrey J. BrunoEmail author
  • Frank P. Tverdek
Reference work entry

Abstract

Oncology patients are often vulnerable to the development of infection. Accordingly, antimicrobial prophylaxis may be necessary. In caring for oncology patients, critical care providers should be astute at determining the risk of infection, identifying patients appropriate for antimicrobial prophylaxis, and assessing the risk-benefit profile of available prophylactic options. Using best available evidence and current guidelines (when applicable), this chapter will provide a framework to guide the critical care clinician in addressing the above considerations for both the surgical population and those with malignancy and/or treatment-related immune compromise. In regard to surgical patients, emphasis will be placed on the prevention of surgical site infections following procedures for the management of malignancy and for which postoperative admission to the intensive care unit may be necessary. The remainder of the chapter will highlight principles for the prevention of bacterial, fungal, and viral infections among the immunocompromised oncology population.

Keywords

Surgical procedures Antimicrobial prophylaxis Surgical site infection Immunocompromised Fungal infection Bacterial infection Pneumocystis Hepatitis Viral infection 

References

  1. 1.
    Alotaibi AF, et al. The efficacy of antibacterial prophylaxis against the development of meningitis after craniotomy: a meta-analysis. World Neurosurg. 2016;90:597–603 e591.  https://doi.org/10.1016/j.wneu.2016.02.048.CrossRefPubMedGoogle Scholar
  2. 2.
    Ancker JS, Witteman HO, Hafeez B, Provencher T, Van de Graaf M, Wei E. The invisible work of personal health information management among people with multiple chronic conditions: qualitative interview study among patients and providers. J Med Internet Res. 2015;17:e137.  https://doi.org/10.2196/jmir.4381.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother. 2016;50:673–9.  https://doi.org/10.1177/1060028016650107.CrossRefPubMedGoogle Scholar
  4. 4.
    Baden LR, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:882–913.CrossRefGoogle Scholar
  5. 5.
    Bernard A, Pillet M, Goudet P, Viard H. Antibiotic prophylaxis in pulmonary surgery. A prospective randomized double-blind trial of flash cefuroxime versus forty-eight-hour cefuroxime. J Thorac Cardiovasc Surg. 1994;107:896–900.PubMedGoogle Scholar
  6. 6.
    Berrios-Torres SI, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152:784–91.  https://doi.org/10.1001/jamasurg.2017.0904.CrossRefPubMedGoogle Scholar
  7. 7.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–40.CrossRefGoogle Scholar
  8. 8.
    Boldt J, Piper S, Uphus D, Fussle R, Hempelmann G. Preoperative microbiologic screening and antibiotic prophylaxis in pulmonary resection operations. Ann Thorac Surg. 1999;68:208–11.CrossRefGoogle Scholar
  9. 9.
    Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–283.  https://doi.org/10.2146/ajhp120568.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown SM, Anand VK, Tabaee A, Schwartz TH. Role of perioperative antibiotics in endoscopic skull base surgery. Laryngoscope 2007;117(9):1528–1532.CrossRefGoogle Scholar
  11. 11.
    Centers for Disease Control C. Procedure-associated Module SSI. 2018. http://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf. Accessed 24 Sept 2018.
  12. 12.
    Chemaly RF, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–9.  https://doi.org/10.1056/NEJMoa1309533.CrossRefPubMedGoogle Scholar
  13. 13.
    Cornely OA, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.  https://doi.org/10.1056/NEJMoa061094.CrossRefPubMedGoogle Scholar
  14. 14.
    Eleutherakis-Papaiakovou E, et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010;85:863–7.  https://doi.org/10.1002/ajh.21855.CrossRefPubMedGoogle Scholar
  15. 15.
    Fried HI, et al. The insertion and management of external ventricular drains: an evidence-based consensus statement: a statement for healthcare professionals from the neurocritical care society. Neurocrit Care. 2016;24:61–81.  https://doi.org/10.1007/s12028-015-0224-8.CrossRefPubMedGoogle Scholar
  16. 16.
    Gafter-Gvili A, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.  https://doi.org/10.1002/14651858.CD004386.pub3.CrossRefPubMedGoogle Scholar
  17. 17.
    Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009;  https://doi.org/10.1002/14651858.CD006706.pub2.
  18. 18.
    Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother. 1987;31:361–7.CrossRefGoogle Scholar
  19. 19.
    Gomes MZ, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of primary anti-aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother. 2014;58:2775–80.  https://doi.org/10.1128/AAC.01527-13.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Haga N, Ishida H, Ishiguro T, Kumamoto K, Ishibashi K, Tsuji Y, Miyazaki T. A prospective randomized study to assess the optimal duration of intravenous antimicrobial prophylaxis in elective gastric cancer surgery. Int Surg. 2012;97:169–76.  https://doi.org/10.9738/CC91.1.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a meta-analysis. Neurosurgery. 1994;34:87–92.PubMedGoogle Scholar
  22. 22.
    Imamura H, et al. Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. Lancet Infect Dis. 2012;12:381–7.  https://doi.org/10.1016/S1473-3099(11)70370-X.CrossRefPubMedGoogle Scholar
  23. 23.
    Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640–51.  https://doi.org/10.1056/NEJMoa054408.CrossRefPubMedGoogle Scholar
  24. 24.
    Johans SJ, Burkett DJ, Swong KN, Patel CR, Germanwala AV. Antibiotic prophylaxis and infection prevention for endoscopic endonasal skull base surgery: our protocol, results and review of the literature. J Clin Neurosci 2018;47:249–253.CrossRefGoogle Scholar
  25. 25.
    Johnson JT, Myers EN, Thearle PB, Sigler BA, Schramm VL Jr. Antimicrobial prophylaxis for contaminated head and neck surgery. Laryngoscope. 1984;94:46–51.CrossRefGoogle Scholar
  26. 26.
    Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58:6993–5.  https://doi.org/10.1128/AAC.04035-14.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kern WV, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–8.  https://doi.org/10.1007/s10096-005-1278-x.CrossRefPubMedGoogle Scholar
  28. 28.
    Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71:260–7.  https://doi.org/10.1002/ajh.10234.CrossRefPubMedGoogle Scholar
  29. 29.
    Korinek AM, Golmard JL, Elcheick A, Bismuth R, van Effenterre R, Coriat P, Puybasset L. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155–62.  https://doi.org/10.1080/02688690500145639.CrossRefPubMedGoogle Scholar
  30. 30.
    Lane-Fall MB, et al. Developing a standard handoff process for operating room-to-ICU transitions: multidisciplinary clinician perspectives from the handoffs and transitions in critical care (HATRICC) Study. Jt Comm J Qual Patient Saf. 2018;44:514–25.  https://doi.org/10.1016/j.jcjq.2018.02.004.CrossRefPubMedGoogle Scholar
  31. 31.
    Law MF, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22:6484–500.  https://doi.org/10.3748/wjg.v22.i28.6484.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86:805–17.  https://doi.org/10.4065/mcp.2011.0247.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Mahajan SN, Ariza-Heredia EJ, Rolston KV, Graviss LS, Feig BW, Aloia TA, Chemaly RF. Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics. Ann Surg Oncol. 2014;21:513–9.  https://doi.org/10.1245/s10434-013-3294-x.CrossRefPubMedGoogle Scholar
  34. 34.
    Marr KA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33.  https://doi.org/10.1182/blood-2003-08-2644.CrossRefPubMedGoogle Scholar
  35. 35.
    Marty FM, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.  https://doi.org/10.1056/NEJMoa1706640.CrossRefPubMedGoogle Scholar
  36. 36.
    Masur H, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1308–11.  https://doi.org/10.1093/cid/ciu094.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    McCarthy PJ, Patil S, Conrad SA, Scott LK. International and specialty trends in the use of prophylactic antibiotics to prevent infectious complications after insertion of external ventricular drainage devices. Neurocrit Care. 2010;12:220–4.  https://doi.org/10.1007/s12028-009-9284-y.CrossRefPubMedGoogle Scholar
  38. 38.
    McCutcheon BA, et al. Predictors of surgical site infection following craniotomy for intracranial neoplasms: an analysis of prospectively collected data in the American college of surgeons national surgical quality improvement program database. World Neurosurg. 2016;88:350–8.  https://doi.org/10.1016/j.wneu.2015.12.068.CrossRefPubMedGoogle Scholar
  39. 39.
    Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16:647–57.CrossRefGoogle Scholar
  40. 40.
    Mitchell RM, Mendez E, Schmitt NC, Bhrany AD, Futran ND. Antibiotic prophylaxis in patients undergoing head and neck free flap reconstruction. JAMA Otolaryngol Head Neck Surg. 2015;141:1096–103.  https://doi.org/10.1001/jamaoto.2015.0513.CrossRefPubMedGoogle Scholar
  41. 41.
    Mohri Y, Tonouchi H, Kobayashi M, Nakai K, Kusunoki M, Mie Surgical Infection Research G. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. Br J Surg. 2007;94:683–8.  https://doi.org/10.1002/bjs.5837.CrossRefPubMedGoogle Scholar
  42. 42.
    Morita S, Nishisho I, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery. Surg Today 2005;35:732–738.CrossRefGoogle Scholar
  43. 43.
    Murphy J, Isaiah A, Dyalram D, Lubek JE. Surgical site infections in patients receiving osteomyocutaneous free flaps to the head and neck. Does choice of antibiotic prophylaxis matter? J Oral Maxillofac Surg. 2017;75:2223–9.  https://doi.org/10.1016/j.joms.2017.02.006.CrossRefPubMedGoogle Scholar
  44. 44.
    Olak J, Jeyasingham K, Forrester-Wood C, Hutter J, Al-Zeerah M, Brown E. Randomized trial of one-dose versus six-dose cefazolin prophylaxis in elective general thoracic surgery. Ann Thorac Surg. 1991;51:956–8.CrossRefGoogle Scholar
  45. 45.
    Pool C, et al. Increased surgical site infection rates following clindamycin use in head and neck free tissue transfer. Otolaryngol Head Neck Surg. 2016;154: 272–8.  https://doi.org/10.1177/0194599815617129.CrossRefPubMedGoogle Scholar
  46. 46.
    Poole CL, James SH. Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 2018;40:1282–98.  https://doi.org/10.1016/j.clinthera.2018.07.006.CrossRefPubMedGoogle Scholar
  47. 47.
    Racano A, Pazionis T, Farrokhyar F, Deheshi B, Ghert M. High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review. Clin Orthop Relat Res. 2013;471:2017–27.  https://doi.org/10.1007/s11999-013-2842-9.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28:331–40.  https://doi.org/10.1086/515128.CrossRefPubMedGoogle Scholar
  49. 49.
    Saunders S, Reese S, Lam J, Wulu J, Jalisi S, Ezzat W. Extended use of perioperative antibiotics in head and neck microvascular reconstruction. Am J Otolaryngol. 2017;38:204–7.  https://doi.org/10.1016/j.amjoto.2017.01.009.CrossRefPubMedGoogle Scholar
  50. 50.
    Schroder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75:207–15.  https://doi.org/10.1016/j.jinf.2017.06.010.CrossRefPubMedGoogle Scholar
  51. 51.
    Severyns M, Briand S, Waast D, Touchais S, Hamel A, Gouin F. Postoperative infections after limb-sparing surgery for primary bone tumors of the pelvis: incidence, characterization and functional impact. Surg Oncol. 2017;26:171–7.  https://doi.org/10.1016/j.suronc.2017.03.005.CrossRefPubMedGoogle Scholar
  52. 52.
    Siyahian A, et al. Prophylaxis for hepatitis B virus reactivation after allogeneic stem cell transplantation in the era of drug resistance and newer antivirals: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018;24:1483–9.  https://doi.org/10.1016/j.bbmt.2018.02.027.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg. 1996;131:1165–71; discussion 1171–1162CrossRefGoogle Scholar
  54. 54.
    Takeyama K, Takahashi S, Maeda T, Mutoh M, Kunishima Y, Matsukawa M, Takagi Y. Comparison of 1-day, 2-day, and 3-day administration of antimicrobial prophylaxis in radical prostatectomy. J Infect Chemother: Off J Jpn Soc Chemother. 2007;13: 320–3.  https://doi.org/10.1007/s10156-007-0540-9.CrossRefGoogle Scholar
  55. 55.
    Taplitz RA et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;JCO1800374.  https://doi.org/10.1200/JCO.18.00374.CrossRefGoogle Scholar
  56. 56.
    Terai A, Ichioka K, Kohei N, Ueda N, Utsunomiya N, Inoue K. Antibiotic prophylaxis in radical prostatectomy: 1-day versus 4-day treatments. Int J Urol. 2006;13:1488–93.  https://doi.org/10.1111/j.1442-2042.2006.01597.x.CrossRefPubMedGoogle Scholar
  57. 57.
    Turna A, Kutlu CA, Ozalp T, Karamustafaoglu A, Mulazimoglu L, Bedirhan MA. Antibiotic prophylaxis in elective thoracic surgery: cefuroxime versus cefepime. Thorac Cardiovasc Surg. 2003;51:84–8.  https://doi.org/10.1055/s-2003-38991.CrossRefPubMedGoogle Scholar
  58. 58.
    van Burik JA, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.  https://doi.org/10.1086/422312.CrossRefPubMedGoogle Scholar
  59. 59.
    Wagner JL, Kenney RM, Vazquez JA, Ghanem TA, Davis SL. Surgical prophylaxis with gram-negative activity for reduction of surgical site infections after microvascular reconstruction for head and neck cancer. Head Neck. 2016;38:1449–54.  https://doi.org/10.1002/hed.24178.CrossRefPubMedGoogle Scholar
  60. 60.
    Wingard JR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.  https://doi.org/10.1182/blood-2010-02-268151.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Winston DJ, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.CrossRefGoogle Scholar
  62. 62.
    Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy P. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379–90.  https://doi.org/10.1016/j.juro.2008.01.068.CrossRefPubMedGoogle Scholar
  63. 63.
    Zimlichman E, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173:2039–46.  https://doi.org/10.1001/jamainternmed.2013.9763.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.The University of Texas MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Todd W. Canada
    • 1
  • Jeffrey J. Bruno
    • 2
  1. 1.Clinical Pharmacy Svcs, Pharmacy Clinical ProgramsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Clinical Pharmacy Specialist – Critical Care / Nutrition SupportThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations